Evidence map›Paper›PMID 41063506›Full record

ArticleHuman vaccines & immunotherapeutics2025

Social media insights on the introduction of RSV immunoprophylaxis in Italy.

Francesco Gesualdo, Virginia Casigliani, Guglielmo Arzilli, Erica De Vita, Andrea Davide Porretta, Ileana Croci, Andrea Carrozzo, Veronica Bartolucci, Cesare Buquicchio, Caterina Rizzo

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Francesco GesualdoDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.ORCID 0000-0002-9087-4398
Virginia CasiglianiDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.ORCID 0000-0002-4184-2648
Guglielmo ArzilliDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Erica De VitaDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Andrea Davide PorrettaDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Ileana CrociPredictive and Preventive Medicine Research Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Andrea CarrozzoDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Veronica BartolucciDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Cesare BuquicchioDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Caterina RizzoDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of new immunoprophylaxis strategies against respiratory syncytial virus (RSV), such as maternal vaccination and the administration of monoclonal antibodies to newborns, presents both opportunities and challenges in terms of public understanding and acceptance. Monitoring online discussions can offer timely insights into perceptions of these interventions. We conducted a social media monitoring activity in Italy from September 2024 to January 2025, using the Pulsar platform to analyze posts on X and Facebook, complemented by manual analysis of comments on Instagram and TikTok. We examined content related to RSV prevention, focusing on stance, recurring narratives, and specific questions or doubts. Most content showed a neutral or supportive stance toward RSV immunoprophylaxis, with many users expressing awareness of RSV risk and interest in accessing the monoclonal antibody. However, recurring information needs emerged around eligibility, access, safety, and the distinction between different prevention options. Criticism toward the government was also observed, linked to initial decisions that limited free provision of the antibody to certain regions, later reversed, which left perceptions of inequality. Only a limited proportion of posts contained clear misinformation or disinformation. These results were consistent with recent surveys in other countries showing high parental acceptance of similar interventions. These findings underscore the need to address specific information gaps and ensure clear, consistent communication to support trust in RSV immunoprophylaxis. Proactive efforts will be important to reinforce the generally positive attitudes observed and to mitigate concerns that could affect the acceptance of new preventive measures.

Indexed as

Respiratory Syncytial Virus InfectionsSocial MediaAntibodies, MonoclonalFemaleHealth Knowledge, Attitudes, PracticeHumansInfant, NewbornItalyRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus VaccinesVaccinationAntibodies, MonoclonalRespiratory Syncytial Virus Vaccinesimmunoprophylaxismisinformationmonoclonal antibodyNirsevimabpublic health communicationrisk communicationRSVsocial listeningsocial media monitoringvaccine confidence

Identifiers

PMID41063506
PMCPMC12520068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.